With increasing pressure to enhance efficiency and reduce costs, AI is transforming diagnostics and patient care by enabling radiologists to make informed decisions, minimize human error, and improve outcomes. CureMetrix is redefining healthcare with innovative AI-powered solutions, particularly in women’s health. Since its founding in 2014, it has leveraged deep learning and AI to revolutionize disease detection, from breast cancer to heart disease, delivering enhanced clinical and financial outcomes globally. Dedicated to advancing patient care and disease detection technologies, CureMetrix focuses on improving survival rates for women worldwide.
CureMetrix’s image analysis platform for mammography showcases its pioneering efforts. Providing radiologists with precise, data-driven tools to assess mammograms enhances decision-making, improves detection accuracy, and reduces unnecessary follow-ups. This reduces patient anxiety and healthcare costs while ensuring the highest standard of care. Its advanced AI algorithms optimize mammography workflows, broadening the impact of global screening programs.
Over the past decade, CureMetrix has partnered with radiologists, cardiologists, and esteemed institutions worldwide, collecting over 5 million images to train and validate its algorithms. This extensive data allows the company to develop highly effective products that integrate seamlessly into existing clinical workflows. Its solutions are intuitive and user-friendly, ensuring radiologists can adopt them effortlessly without disrupting their busy routines. From breast cancer detection to monitoring heart and kidney disease, CureMetrix extends the value of screening programs, saving lives on a global scale.
CureMetrix’s focus on reducing false positives is particularly impactful. Preliminary studies demonstrate its algorithms significantly lower recall rates associated with unnecessary follow-up procedures. By helping radiologists identify and prioritize suspicious anomalies with precision, CureMetrix minimizes patient stress and inconvenience. This accuracy is vital in a field where early detection of changes in mammograms can be the key to better patient outcomes.
We harness the power of AI to transform disease detection, delivering precise tools that empower radiologists, improve outcomes, and set a new global standard for women’s healthcare. — Navid Alipour, CEO
One of the standout products from CureMetrix is cmAngio®, an FDA-cleared AI software designed to identify breast arterial calcifications (BAC), an incidental finding in mammograms. While typically considered benign, BAC can be an early indicator of cardiovascular issues, and by incorporating this data into the overall patient assessment, CureMetrix is enabling radiologists to provide more comprehensive care. The cmAngio software is designed to work across all breast densities and is HIPAA-compliant, ensuring secure patient data management. It seamlessly integrates with any DICOM-compliant viewer, making it a versatile addition to any imaging system.
Complementing cmAngio is cmAssist®, another AI-powered software tool that helps radiologists identify, mark, and score regions of interest in mammograms. This AI-based computer-aided detection (CAD) system has demonstrated impressive results, improving the detection of cancers by 27% on average without increasing recalls. It operates efficiently across all breast densities, lesion sizes, and types, including both masses and calcifications, ensuring that no anomaly goes unnoticed. cmAssist’s high sensitivity and ability to minimize false positives make it an invaluable tool in the radiologist’s arsenal, ensuring quicker and more accurate diagnoses.
In addition to these diagnostic tools, CureMetrix has introduced cmTriage®, a workflow optimization tool designed to help radiologists prioritize cases based on the presence of suspicious findings. This FDA-cleared software enables the sorting and triaging of mammograms, ensuring that the most urgent cases are addressed first. By intelligently managing the radiology worklist, cmTriage helps improve clinical efficiency and ensures that patients receive the timely care they need.
Furthermore, CureMetrix offers cmDensity®, a tool designed to assist radiologists in accurately classifying breast density. Dense breast tissue can obscure the detection of cancers on mammograms, and cmDensity helps mitigate this challenge by automating the classification process and improving consistency. It enhances the efficiency of radiologists by automatically populating reports with density classifications, reducing intra and inter-reader variability, and ensuring that mammography centers meet FDA density reporting requirements.
CureMetrix is a true leader in advancing the field of radiology. With its powerful tools for mammography, heart health, and beyond, CureMetrix is setting a new standard for how AI can be integrated into clinical workflows to support better healthcare for women globally.